Flagship Biosciences Inc. software

Your next pathology-based CDx starts here. With the complexity of therapies increasing, the need for a robust companion diagnostic (CDx) has never been higher. Advances in tissue analysis technologies now require a more quantitative, accurate, and precise pathology-based CDx. Bringing your CDx to market requires a solid strategy to meet strict regulatory standards and critical timelines. Your CDx pipeline needs a trusted partner with expertise in novel biomarker and tissue analysis and CDx development.